Beta Drugs (NSE:BETA) EV-to-EBIT : 21.84 (As of Jun. 06, 2024)

Beta Drugs EV-to-EBIT Chart

Beta Drugs Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
EV-to-EBIT		Get a 7-Day Free Trial					3.91	6.74	15.15	13.89	22.66

Beta Drugs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial														15.15	-	13.89	-	22.66

Competitive Comparison of Beta Drugs's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Drugs's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beta Drugs's EV-to-EBIT falls into.

Beta Drugs EV-to-EBIT Calculation

Beta Drugs's EV-to-EBIT for today is calculated as:

Beta Drugs's current Enterprise Value is ₹11,264 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹516 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs  (NSE:BETA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Beta Drugs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Beta Drugs's Enterprise Value for the quarter that ended in Mar. 2024 was ₹11,684 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹516 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Beta Drugs's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Beta Drugs (NSE:BETA) Business Description